Table I.
Patient and disease characteristics
| Rigosertib b.i.d. Dosing (mg) for 2 out of 3 weeks | Total | |||||
|---|---|---|---|---|---|---|
| 70 | 140 | 280 | 560 | 700 | ||
| Patients (n) | 3 | 2 | 2 | 24 | 6 | 37 |
| Sex | 3F | 1M/1F | 2M | 15M/9F | 5M/1F | 23M/14F |
| Age range (years) | 64–82 | 74–84 | 73–76 | 56–89 | 53–82 | 53–89 |
| Duration of treatment (weeks) | 4–18 | 9–34 | 11–31 | 1–53+ | 5–17 | 1–53+ |
| Prior azacitidine/decitabine treatment | 3 | 2 | 2 | 15 | 5 | 27 |
The study population included 23 male and 14 female patients with myelodysplastic syndrome (MDS), with a median age of 74 years (range 53 to 89 years). The study included 16 (43%) patients with refractory anaemia with excess blasts (RAEB)-1 or -2, and 21 (57%) patients with refractory cytopenia with multilineage dysplasia, as defined by the World Health Organization classification of MDS (Vardiman et al 2009). In terms of IPSS scores, 23 (62%) patients were in the low or intermediate-1 risk categories, and 14 (38%) patients were in the intermediate-2 or high-risk categories. The majority (73%) of patients had been previously treated with azanucleosides (azacitidine and/or decitabine). F, female; M, male.